Scott Walsman, MD
Ophthalmology · Jersey City, NJNPI 1215172994
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. AbbVie accounts for 84.4% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $44,513 and has fallen 91.6% since, to $3,757 in 2025. Among ophthalmology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 273 payments — averaging $341.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$79K
- Glaukos Corporation$13K
- Sight Sciences, Inc.$329
- Alcon$285
- Aerie Pharmaceuticals, Inc.$272
- Bausch & Lomb, A Division Of Bausch Health US, LLC$219
- plus $920 from 16 others
Across 8 payments — averaging $2244.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$18K
What the payments were for
- Consulting fees$36,38839%
- Speaking & faculty fees$45,12548%
- Travel & lodging$5,3306%
- Food & beverage$6,4177%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 186 | $78,726 |
| Glaukos Corporation | 15 | $12,510 |
| Sight Sciences, Inc. | 7 | $329 |
| Alcon | 10 | $285 |
| Aerie Pharmaceuticals, Inc. | 6 | $272 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 11 | $219 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $186 |
| NEW World Medical,inc. | 3 | $143 |
| Bausch & Lomb Americas Inc. | 1 | $125 |
| Mallinckrodt Hospital Products Inc. | 5 | $94 |
| Tarsus Pharmaceuticals, Inc. | 3 | $59 |
| Biotissue Holdings Inc. | 3 | $47 |
| Sun Pharmaceutical Industries Inc. | 3 | $44 |
| Novartis | 3 | $43 |
| Kala Pharmaceuticals, Inc. | 2 | $35 |
| Ivantis, Inc | 2 | $29 |
| Ocular Therapeutix, Inc. | 2 | $27 |
| Travere Therapeutics, Inc. | 1 | $21 |
| Thea Pharma Inc. | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
| Eyepoint US, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMIGAN$38,597
- RESTASIS$17,543
- COMBIGAN$9,495
- DURYSTA$9,213
- XEN$7,994
- ALPHAGAN P$5,200
- iDose$4,447
- iStent infinite Trabecular Micro-Bypass System Model iS3$2,307
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$2,013
- iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3$295
- enVista MX60 IOL$250
- OMNI(R) SURGICAL SYSTEM (US)$222
- PHOTREXA CROSS-LINKING KIT$131
- Centurion$126
- LOTEMAX SM$125
- enVista Aspire IOL$125
- Rocklatan$118
- Rhopressa$118
- Kahook Dual Blade$103
- Streamline Surgical System$103
How this compares
$93,260 in reported general payments places this provider in the 95th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 436 | $231,662 |
| CombiganBrimonidine Tartrate/Timolol | 141 | $60,181 |
| Prednisolone Acetate | 757 | $40,370 |
| VyzultaLatanoprostene Bunod | 59 | $31,756 |
| RocklatanNetarsudil Mesylat/Latanoprost | 76 | $28,326 |
| RestasisCyclosporine | 30 | $26,108 |
| RhopressaNetarsudil Mesylate | 53 | $23,849 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 158 | $21,448 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 85 | $17,879 |
| Bromfenac Sodium | 59 | $12,736 |
| Travoprost | 77 | $11,342 |
| Brimonidine Tartrate | 221 | $11,324 |
| Latanoprost | 880 | $9,967 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 585 | $7,963 |
| Alphagan PBrimonidine Tartrate | 15 | $6,258 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $78,726 | $324,209622 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $272 | $52,175129 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $125 | $31,75659 claims |
| AlconSimbrinza | $285 | $17,87985 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $219 | $5,23913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Jersey City
- Kunjal ModiJersey City$24K
- Ganesh RauJersey City$11K
- Jai ParekhWoodland Park$2M
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$655K
- Eric MannDover$604K
- Brett BieloryRutherford$477K
- Albert KhouriNewark$428K
- Robert FechtnerNewark$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.